Dr Paul Kemp, lead inventor of Apligraf® the first FDA-approved multi-cell therapy, joins CellResearch Corporation (CRC), a Singaporean stem cell biotech company, to aid the development of wound healing therapeutics using CRC’s patented cord lining technology
- Dr Paul Kemp, one of the pre-eminent global experts on cellular therapies, and lead inventor of the first multi-cell therapy (Apligraf®) approved by FDA (Food and Drug Administration) joins CRC’s Scientific Advisory Board to facilitate and advise on the development of its products CorLiCyteTM and SollagenTM.
- CorLiCyteTM is an umbilical cord lining stem cell therapy for patients suffering with Diabetic Foot Ulcers (DFU), SollagenTM is a brand targeting Diabetic skin.
- The need for targeted diabetic skin care is pressing as the global diabetes patient population is set to grow to 783 million in 20451 from 537 million in 2021.
- DFU is a global health emergency that will affect close to 20% of the diabetic population in their lifetime1.
- 5-year mortality and direct costs of care for people with diabetic foot complications are comparable to those of cancer2.
25th August 2022 Singapore: Singapore biotech company CellResearch Corporation has appointed former Organogenesis Executive and Lead Inventor of Apligraft® Paul Kemp (PhD) to its Scientific Advisory Board.
Dr Paul Kemp is one of the foremost experts in the field of cellular therapy for wound healing. At Organogenesis Inc, he was the lead inventor on patents for one of the first cell therapies approved by the FDA. He was involved in all stages of the development of this product from the bench, through the clinical trial process, development of a licensing and marketing partnership and the eventual approval and launch in the US. This product has now treated well over half a million patients and is the largest selling manufactured cell therapy in the world.
Dr Kemp has over 25 years of experience in building numerous cellular therapy products and businesses. He has experience across the whole life cycle of product development, regulatory approval, and commercialisation. “Dr Kemp is a phenomenal addition to our Scientific Advisory Board; he is a pioneer in the space of cellular therapy and has led products like ours all the way to successful commercialisation. He will be an invaluable sounding board going forward and we are incredibly pleased that he has agreed to join us.” noted Gavin Tan, CEO of CRC.
Dr Kemp added “Cellular therapy has already demonstrated its ability to positively impact the healing of diabetic wounds. I am very excited to be able to use my experience in this area to help in the development of this next generation of cell therapy treatments.”
Dr Kemp has many patents and publications in the field. He is co-editor of the Journal of Regenerative Medicine, a co-Director of the Doctoral Training Centre in Regenerative Medicine at Manchester University and Industrial Director of Regener8.
This news comes at an opportune moment given the imminent completion of CRC’s Phase 1 USFDA trial to close chronic DFUs (Diabetic Foot Ulcers) at the University of Colorado Anschutz Medical Campus under the identifier NCT04104451.
1 Yazdanpanah L, et al. Incidence and Risk Factors of Diabetic Foot Ulcer: A Population-Based Diabetic Foot Cohort (ADFC Study)-Two-Year Follow-Up Study. Int J Endocrinol. 2018;2018:7631659. Published 2018 Mar 15. doi:10.1155/2018/7631659
2 Armstrong DG, Swerdlow MA, Armstrong AA, Conte MS, Padula WV, Bus SA. Five year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer. J Foot Ankle Res. 2020 Mar 24;13(1):16. doi: 10.1186/s13047-020-00383-2. PMID: 32209136; PMCID: PMC7092527.
About CellResearch Corporation (CRC)
CellResearch Corporation was founded in 2002 as a contract research provider focusing on skin cells. In 2004, the company made the discovery that the umbilical cord lining of mammals was an abundant source of both mesenchymal and epithelial stem cells. Today, the company owns this technology through a family of patents and holds the rights to commercialise this technology in most major markets globally. While the closure of diabetic foot ulcers is the company's first allogeneic therapy to make it to the end of Phase 1 USFDA clinical trials, CellResearch Corp has a broad therapeutic pipeline at the pre-clinical stage. Further therapies include solid tumour therapy, inflammatory diseases, cardiac muscle repair, Parkinson's Disease, Age-related Macular Degeneration and Diabetes.
CALECIM® Cosmeceuticals is a wholly owned subsidiary of CellResearch Corp and produces an innovative range of skin and hair care products using cord lining stem cell media to power its products. Its range is used in medical aesthetic clinics for anti-aging and hair loss treatments, as well at home as part of a maintenance regime. Its products are distributed globally through over 600 aesthetic physicians and online via its own website. The brand has a key distribution partnership with Menarini Group across South East Asia.
CellResearch Corp partner, Cordlife offers parents the opportunity to bank their child's umbilical cord tissue alongside their cord blood. Cordlife has what is believed to be the largest licensed bank of umbilical cord tissue globally. As cell therapies move into the clinic, Cordlife will have the ability to expand stem cells from a banked umbilical cord for autologous and donor-related uses.
www.cellresearchcorp.com
https://calecimprofessional.com
Business Development and Investor Relations:
Xavier Simpson T:+65 8815 6139 E: xaviersimpson@cellresearchcorp.com